Pyrilamine
Prefrin-a (pyrilamine) is a small molecule pharmaceutical. Pyrilamine was first approved as Prefrin-a on 1982-01-01. It is used to treat allergic conjunctivitis, allergic rhinitis perennial, allergic rhinitis seasonal, and pruritus in the USA. The pharmaceutical is active against histamine H1 receptor. In addition, it is known to target histamine H4 receptor.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Phenylephrine hydrochloride
+
Pyrilamine maleate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PREFRIN-A | Allergan | N-007953 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| menstrual complete | OTC monograph not final | 2023-06-13 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic conjunctivitis | EFO_0007141 | D003233 | H10.44 |
| allergic rhinitis perennial | EFO_1001417 | D012221 | J30.89 |
| allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
| pruritus | HP_0000989 | D011537 | L29 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D04: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04A: Antipruritics, incl. antihistamines, anesthetics, etc.
— D04AA: Antihistamines for topical use
— D04AA02: Mepyramine
R: Respiratory system drugs
— R03: Drugs for obstructive airway diseases
— R03D: Other systemic drugs for obstructive airway diseases in atc
— R03DA: Xanthines, systemic for obstructive airway disease
— R03DA12: Mepyramine theophyllinacetate
— R06: Antihistamines for systemic use
— R06A: Antihistamines for systemic use
— R06AC: Substituted ethylene diamines, systemic antihistamines
— R06AC01: Mepyramine
HCPCS
No data
Clinical
Clinical Trials
231 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Tuberculosis | D014376 | EFO_0000774 | A15-A19 | 2 | 5 | 5 | 1 | 6 | 18 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | — | 4 | 1 | 4 | 1 | 9 |
| Neoplasms | D009369 | C80 | 2 | 1 | 3 | 2 | 1 | 8 | |
| Aging | D000375 | GO_0007568 | R41.81 | — | — | — | 3 | 3 | 6 |
| Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 1 | 3 | 1 | — | 5 |
| Epilepsy | D004827 | EFO_0000474 | G40.9 | — | 1 | — | 1 | 2 | 4 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | 2 | 1 | 1 | 4 |
| Latent tuberculosis | D055985 | Z22.7 | 1 | — | — | 1 | 1 | 3 | |
| Macular degeneration | D008268 | EFO_0001365 | H35.30 | — | — | — | 2 | 1 | 3 |
| Morning sickness | D048968 | — | — | 1 | 1 | — | 2 |
Show 18 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 2 | 7 | — | 8 | 18 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | 3 | — | — | 7 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | 2 | 1 | — | 1 | 4 |
| Colorectal neoplasms | D015179 | — | 2 | 2 | — | 1 | 4 | ||
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 2 | — | 2 | 4 |
| Schizophrenia | D012559 | EFO_0000692 | F20 | 1 | 2 | 1 | — | 1 | 3 |
| Psychotic disorders | D011618 | F20.81 | 1 | 2 | 1 | — | 1 | 3 | |
| Alzheimer disease | D000544 | EFO_0000249 | F03 | — | — | 2 | — | 1 | 3 |
| Pulmonary tuberculosis | D014397 | EFO_1000049 | A15 | — | 2 | 1 | — | — | 3 |
| Tardive dyskinesia | D000071057 | G24.01 | — | 1 | 1 | — | 1 | 3 |
Show 39 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | 2 | 1 | — | — | 4 | 7 | ||
| Hiv | D006678 | O98.7 | 2 | 3 | — | — | 1 | 5 | |
| Lymphoma | D008223 | C85.9 | 3 | 4 | — | — | — | 4 | |
| Autism spectrum disorder | D000067877 | F84.0 | — | 2 | — | — | 2 | 4 | |
| Prostatic neoplasms | D011471 | C61 | — | 1 | — | — | 2 | 3 | |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | 1 | — | — | 1 | 2 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | — | 1 | — | — | 1 | 2 |
| Coronary disease | D003327 | — | 1 | — | — | — | 1 | ||
| Heart diseases | D006331 | EFO_0003777 | I51.9 | — | 1 | — | — | — | 1 |
| Nodding syndrome | D064128 | — | 1 | — | — | — | 1 |
Show 15 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasm metastasis | D009362 | EFO_0009708 | 1 | — | — | — | — | 1 | |
| Biological availability | D001682 | 1 | — | — | — | — | 1 | ||
| Triple negative breast neoplasms | D064726 | 1 | — | — | — | — | 1 | ||
| Male breast neoplasms | D018567 | 1 | — | — | — | — | 1 | ||
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Myeloid leukemia acute | D015470 | C92.0 | 1 | — | — | — | — | 1 | |
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | 1 | — | — | — | — | 1 | |
| Prostatic intraepithelial neoplasia | D019048 | N42.31 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Avitaminosis | D001361 | EFO_0005878 | E56.9 | — | — | — | — | 4 | 4 |
| Vitamin d deficiency | D014808 | EFO_0003762 | E55 | — | — | — | — | 3 | 3 |
| Iron-deficiency anemia | D018798 | HP_0001891 | D50 | — | — | — | — | 3 | 3 |
| Healthy diet | D000072001 | — | — | — | — | 3 | 3 | ||
| Female infertility | D007247 | EFO_0008560 | N97 | — | — | — | — | 2 | 2 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 2 | 2 |
| Obesity | D009765 | EFO_0001073 | E66.9 | — | — | — | — | 2 | 2 |
| Aggression | D000374 | EFO_0003015 | — | — | — | — | 2 | 2 | |
| Traumatic brain injuries | D000070642 | S06 | — | — | — | — | 2 | 2 | |
| Cognitive dysfunction | D060825 | G31.84 | — | — | — | — | 2 | 2 |
Show 48 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PYRILAMINE |
| INN | mepyramine |
| Description | Mepyramine is an ethylenediamine derivative that is ethylenediamine in which one of the amino nitrogens is substituted by two methyl groups and the remaining amino nitrogen is substituted by a 4-methoxybenzyl and a pyridin-2-yl group. It has a role as a H1-receptor antagonist. It is an ethylenediamine derivative and an aromatic ether. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | COc1ccc(CN(CCN(C)C)c2ccccn2)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 91-84-9 |
| RxCUI | 9009 |
| ChEMBL ID | CHEMBL511 |
| ChEBI ID | 6762 |
| PubChem CID | 4992 |
| DrugBank | DB06691 |
| UNII ID | HPE317O9TL (ChemIDplus, GSRS) |
Target
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 2,983 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
3,268 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more